CHMP has recommended approval of Gavreto, which Roche is developing with partners. The drug is intended to treat non-small cell lung cancer. If approved by the European Commission, Gavreto will become the first drug to treat advanced NSCLC in Europe. This disease affects 37,500 people worldwide every year. In Europe, Roche holds the exclusive rights to commercialize Gavreto.